Chemopreventive efficacies of rosiglitazone, fenretinide and their combination against rat mammary carcinogenesis

KOÇDOR H., KOÇDOR M. A., Canda T., GÜREL D., Cehreli R., YILMAZ O., ...More

CLINICAL & TRANSLATIONAL ONCOLOGY, vol.11, no.4, pp.243-249, 2009 (SCI-Expanded, Scopus) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 11 Issue: 4
  • Publication Date: 2009
  • Doi Number: 10.1007/s12094-009-0347-5
  • Journal Name: CLINICAL & TRANSLATIONAL ONCOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.243-249
  • Keywords: Chemoprevention, DMBA, Rosiglitazone, Fenretinide, Mammary carcinogenesis
  • Dokuz Eylül University Affiliated: Yes

Abstract

Peroxisome proliferator-activated receptor gamma (PPAR-gamma) and retinoic acid receptors (RAR/RXR) belong to the nuclear steroid receptor family. In vitro studies have suggested that PPAR-gamma ligands are highly effective in preventing mammary tumours and these effects are enhanced by some retinoids. However, in vivo anti-initiator and anti-promoter efficacies of this combination are not clear.